Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer

British Journal of Cancer

Volumn 85, Issue 11, 2001, Pages 1753-1758

  McPhillips, F ^a   Mullen, P ^a   Monia, B P ^b   Ritchie, A A ^a   Dorr, F A ^b   Smyth, J F ^a   Langdon, S P ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense; Cancer; Oligodeoxynucleotide; Ovarian; Raf

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; ISIS 13650; RAF PROTEIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; XENOGRAFT;

ANIMALS; CELL CYCLE; CELL DIVISION; DNA, ANTISENSE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-RAF; SURVIVAL ANALYSIS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035977185     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2139     Document Type: Article

References (25)

1. Rat meets Ras: Completing the framework of a signal transduction pathway
2. Antisense oligonucleotide inhibition of serine/threonine kinases: An innovative approach to cancer treatment
3. In vitro and in vivo activity of antisense inhibitors of ras: Potential for clinical development
4. The inns and outs of rat kinases
5. Therapeutic application of anti-growth factor receptor antibodies
6. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
7. Characterization and properties of nine human ovarian adenocarcinoma cell lines
8. Abrogation of c-Raf expression induces apoptosis in tumour cells
9. DNA analysis of breast tumour fine needle aspirates using flow cytometry
10. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: A new prognostic factor
11. First- and second-generation antisense inhibitors targeted to human c-Raf kinase: In vitro and in vivo studies
12. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-Raf kinase
13. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human c-Raf kinase supports an antisense mechanism of action in vivo
14. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer
15. c-Raf-1 depletion and tumor responses in patients treated with the c-Raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A)
16. The Rat oncogenes
17. Role of rat oncogenes in lung carcinogenisis
18. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1
19. Expression of epidermal growth factor receptor in normal ovary and in ovarian tumors
20. Raf oncogenes in carcinogenesis
21. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms
22. United Kingdom co-ordinating committee on cancer research (UKCCCR) Guidelines for the welfare of animals in experimental neoplasia
23. Antisense oligonucleotides to the epidermal growth factor receptor
24. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP64128A) in patients with cancer
25. Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases